Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cellular Oncology
Published in: Cellular Oncology 1/2018

01-02-2018 | Letter to the Editor

Metabolic iodine and tumours

Author: D. S. Robertson

Published in: Cellular Oncology | Issue 1/2018

Login to get access

Abstract

Purpose

Purpose of the work is to highlight a possible connection between metabolic iodine and natural tumour control.

Method

Method adopted is to use information available in the literature.

Result

Result indicated a means of the purpose being attained.

Conclusion

Conclusion drawn is that a tumour control method derives from the relationship studied.
Literature
1.
A. Mancini, E. Giacchi, S. Raimondo, C. Di Segni, A. Silvestrini, and E. Meucci, Hypothyroidism, oxidative stress and reproduction, in Hypothyroidism—Influences and Treatments, pp. 117–134, InTech, Rijeka, Croatia, 2012
2.
D.S. Robertson, Cellular formation of DNA and RNA and the relationship to tumour cell development. Med Hypothesis 62, 97–111 (2004)CrossRef
3.
D.S. Robertson, The cyclic change in the valency state of iron in the human metabolism. Haema 9, 367–370 (2006)
4.
F. Ahad, S.A. Ganie, Iodine, iodine metabolism and iodine deficiency disorders revisited. Indian J Endocrinol Metab 14, 13–17 (2010)
5.
C. Aceves, B. Anguiano, G. Delgado, The extrathyronine actions of iodine as antioxidant, apoptotic, and differentiation factor in various tissues. Thyroid 23, 938–946 (2013)
6.
F. Golkowski, Z. Szybinski, J. Rachtan, A. Sokolowski, M. Buziak-Bereza, M. Trofimiuk, A. Hubalewska-Dydejczyk, E. Przybylik-Mazurek, B. Huszno, Iodine prophylaxis--the protective factor against stomach cancer in iodine deficient areas. Eur J Nutr 46, 251–256 (2007)
7.
S.B. Schwarz, N. Thon, N. Nikolajek, M. Niyazi, J.-C. Tonn, C. Belka, F.-W. Kreth, Iodine-125 brachytherapy for brain tumours - a review. Radiat Oncol 20, 127–130 (2012)
8.
R.G. Gottschalk, L.K. Alpert, R.E. Albert, The Use of Large Amounts of Radioactive Sulfur in Patients with Advanced Chondrosarcomas I. Clinical and Hematologic Observations. Cancer Res 19, 1078–1108 (1959)
9.
G. Sokhi, The Management of Terminal Carcinoma with Oral Potassium Permanganate. Br J Cancer 24, 290–293 (1970)
10.
B. Baker, L.I.G. Worthley, The essentials of calcium, magnesium and phosphate metabolism: Part I. Physiology. Crit Care and Resusc 4, 301–306 (2002)
11.
Lobo, D.N. Physiological Aspects of Fluid and Electrolyte Balance. Submitted to the University of Nottingham for the degree of Doctor of Medicine. 2002
Metadata
Title
Metabolic iodine and tumours
Author
D. S. Robertson
Publication date
01-02-2018
Publisher
Springer Netherlands
Published in
Cellular Oncology / Issue 1/2018
Print ISSN: 2211-3428
Electronic ISSN: 2211-3436
DOI
https://doi.org/10.1007/s13402-017-0350-8

Other articles of this Issue 1/2018

Cellular Oncology 1/2018 Go to the issue

Original Paper

Lithocholic bile acid inhibits lipogenesis and induces apoptosis in breast cancer cells

Original Paper

A2B adenosine receptor agonist induces cell cycle arrest and apoptosis in breast cancer stem cells via ERK1/2 phosphorylation

Original Paper

Memory CD4+ T cell subsets in tumor draining lymph nodes of breast cancer patients: A focus on T stem cell memory cells

Original Paper

Serum exosomal miR-301a as a potential diagnostic and prognostic biomarker for human glioma

Report

Implications of FGF19 on sorafenib-mediated nitric oxide production in hepatocellular carcinoma cells - a short report

Original Paper

Diterpenoid natural compound C4 (Crassin) exerts cytostatic effects on triple-negative breast cancer cells via a pathway involving reactive oxygen species
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits